Voclosporin + Placebo Oral Capsule

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Nephritis

Conditions

Lupus Nephritis

Trial Timeline

May 17, 2017 โ†’ Oct 10, 2019

About Voclosporin + Placebo Oral Capsule

Voclosporin + Placebo Oral Capsule is a phase 3 stage product being developed by Aurinia Pharmaceuticals for Lupus Nephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03021499. Target conditions include Lupus Nephritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT05288855Phase 3Terminated
NCT03597464Phase 3Completed
NCT03021499Phase 3Completed

Competing Products

20 competing products in Lupus Nephritis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
tacrolimusAstellas PharmaPhase 3
77
TacrolimusAstellas PharmaPre-clinical
23
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
77
tacrolimusAstellas PharmaApproved
85
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
77
E6742EisaiPhase 1/2
41
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 1
33
LY3471851 + PlaceboEli LillyPhase 2
52